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Aim: To study whether a simple targeted intervention could reduce unwarranted an-
tibiotic treatment in near-term and term neonates with suspected, but not confirmed 
early-onset sepsis.
Methods: A quality improvement initiative in three Norwegian neonatal intensive care 
units. The intervention included an inter-hospital clinical practice guideline for dis-
continuing antibiotics after 36-48 hours if sepsis was no longer suspected and blood 
cultures were negative in neonates ≥ 34+0 weeks of gestation. Two units used procal-
citonin in decision-making. We compared data 12-14 months before and after guideline 
implementation. The results are presented as median with interquartile ranges.
Results: A total of 284 infants (2.5% of all births ≥ 34+0 weeks of gestation) re-
ceived antibiotics before and 195 (1.8%) after guideline implementation (P = .0018). 
The two units that used procalcitonin discontinued antibiotics earlier after guideline 
implementation than the unit without procalcitonin. Neonates not diagnosed with 
sepsis were treated 49 (31-84) hours before and 48 (36-72) hours after guideline im-
plementation (P = .68). In all infants, including those diagnosed with sepsis, antibiotic 
treatment duration was reduced from 108 (60-144) to 96 (48-120) hours (P = .013).
Conclusion: Antibiotic treatment duration for suspected, but not confirmed early-
onset sepsis did not change. However, treatment duration for all infants and the pro-
portion of infants commenced on antibiotics were reduced.
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1  | INTRODUC TION
Due to the challenges of early diagnosis and a potential fatal out-
come if treatment is delayed, clinicians often empirically administer 
intravenous (IV) antibiotics to newborns at risk or with subtle signs of 
early-onset sepsis (EOS).1,2 However, prolonged antibiotic treatment 
is associated with adverse effects on the individual and societal level, 
including frequent exposure to painful procedures, parent-infant 
separation and antibiotic resistance.3,4 Recent clinical initiatives 5 and 
current international guidelines 6,7 strongly recommend discontinua-
tion of antibiotics within 36-48 hours (h) if blood cultures remain neg-
ative and the clinical suspicion of EOS has substantially decreased.
A population-based study in Norway 2009-11 showed that 2.3% 
of all term neonates received IV antibiotics in the first week of life, 
but only 0.05% had a positive blood culture.8 The number needed 
to treat for one culture-proven infection was 44, which is relatively 
low compared with many other countries.9 However, the median 
treatment duration in infants commenced on antibiotics but not di-
agnosed with sepsis was four days (96h), substantially longer than 
recommended.
A large multicentre study showed that procalcitonin (PCT)-
guided decision-making was superior to standard care in reducing 
unwarranted antibiotic treatment of neonates with suspected, but 
not confirmed EOS.9 Implementing an ‘automatic stop order (ASO)’ 
after 48-h antibiotic treatment is another approach to reduce anti-
biotic overuse. Treatment beyond 48 h then requires clinical assess-
ment and justification. ASO reduced prolonged and unnecessary 
antibiotic therapy in some studies.10,11
We performed a quality improvement (QI) project in three 
Norwegian neonatal intensive care units (NICUs) after developing a 
joint inter-hospital clinical practice guideline (CPG). The primary goal 
of this study was to investigate whether a simple targeted interven-
tion using this CPG could reduce unwarranted antibiotic therapy in 
near-term and term infants with suspected, but not confirmed EOS.
2  | PATIENTS AND METHODS
2.1 | Setting and study design
The QI project was designed as a collaborative effort between the 
NICUs at Akershus University Hospital (AHUS), Ostfold Hospital 
Trust (OHT) and University Hospital of North Norway (UNN). All 
three hospitals have a well-defined catchment area and are suited 
for population-based studies. A common CPG entitled ‘Active an-
tibiotic discontinuation in near-term and term neonates’ was devel-
oped in 2016. The CPG was intended to support clinicians’ decision 
to discontinue antibiotics in infants ≥ 34+0 weeks of gestation when 
symptoms and laboratory findings after 36-48 hours made EOS a 
less likely diagnosis. The CPG consisted of a simple bundle with the 
following two main elements. First, we introduced an ASO for antibi-
otics after 48 hours. Second, we recommended discontinuing antibi-
otics within 36-48 hours if the newborn's symptoms had improved, 
there was an absence of persistent respiratory or cardiovascular 
symptoms and/or a more likely underlying cause of the symptoms 
had been identified. In addition, it was strongly recommended to 
trust a negative blood culture result after 36-48 hours.11
In Norway, there is no universal screening for rectovaginal coloni-
sation with group B streptococcus in asymptomatic pregnant women, 
and prophylactic antibiotics are not routinely given to newborn in-
fants of mothers with chorioamnionitis. Norwegian NICUs use a be-
ta-lactam (ampicillin or benzylpenicillin) and gentamicin as empiric 
therapy for suspected EOS.8 There is no national guideline on when 
to initiate antibiotic therapy in newborn infants with risk factors for 
and/or symptoms of EOS, but most units strongly emphasise clinical 
symptoms and seldom start antibiotics based on risk factors alone.
C-reactive protein (CRP) is extensively used as a biomarker for 
EOS in Norway, and it was left to the discretion of the attending phy-
sician to define ‘reassuring’ values. Two of the NICUs (OHT and UNN) 
included PCT as a new biomarker in the CPG. PCT was analysed at 
onset of antibiotic therapy and after 24-36 hours. We used previously 
published reference values for PCT the first week of life.12 The CPG 
was based on international guidelines and initiatives 5,7,13 and recent 
research.9 In all three NICUs, we provided education to the physicians 
and nursing staff about the CPG and its evidence base. Moreover, 
small pamphlets with information about the QI project were dissemi-
nated. Importantly, as the aim of the project was to reduce treatment 
duration in infants already commenced on antibiotics, and not to 
change criteria for initiating therapy, the local guidelines on which risk 
factors, clinical symptoms and findings that should prompt antibiotic 
treatment were not changed in the participating units.
2.2 | Study period, participants and data extraction
The QI project was launched in October-November 2016. We decided 
a priori to evaluate the project by comparing data from all three NICUs 
12-14 months prior to and 12-14 months after guideline implemen-
tation. Background data were extracted from the Norwegian neo-
natal network's (NNN) web-based electronic database, that includes 
Key notes
• This study compared antibiotic treatment duration in 
suspected early-onset sepsis in three Norwegian neona-
tal intensive care units before and after implementation 
of an evidence-based guideline.
• We observed a reduction in treatment duration in all in-
fants commenced on antibiotics; but not in infants not 
diagnosed with sepsis.
• Increased focus on reducing unwarranted antibiotic 
treatment resulted in a lower proportion of near-term 
and term infants receiving antibiotics after guideline 
implementation.
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clinical data and day-to-day treatment of all infants admitted to a 
Norwegian NICU.8 We included all infants with a gestational age (GA) 
≥34 + 0 weeks who received IV antibiotics in the first week of life. 
Duration of antibiotic therapy was counterchecked with drug pre-
scription files, and we extracted hours of therapy from the first to the 
last dose of antibiotic. We summarised the total number of treatment 
days for each of the two periods by adding hours from the first to the 
last dose for all infants receiving antibiotics, divided by the number of 
infants born at the three hospitals. Other data extracted were birth-
weight, gestational age, delivery route, symptoms, respiratory sup-
port, CRP and PCT values at disease onset and during the following 
24-48 hours, and blood culture result. Readmissions within 14 days, 
relevant sequelae and fatalities were also registered.
2.3 | Ethical considerations
The project was approved by the Regional Committee for Medical 
Research Ethics South East as a QI project with no need for individ-
ual consent from the parents of infants included in the project, as 
the project intervention was considered the new ‘standard of care’.
2.4 | Definitions and statistical analysis
According to the International Statistical Classification of Diseases 
and Related Health Problems 10th revision, the diagnosis ‘Unspecified 
bacterial sepsis’ (P36.9) is used when there are clinical and biochemical 
signs of sepsis, but a negative or missing blood culture. The Norwegian 
Paediatric Association has suggested the following criteria for the di-
agnosis: (a) clinical signs of infection, (b) maximum CRP > 30 mg/L, (c) 
≥5 days of antibiotic treatment and (d) exclusion of other explanations 
for the clinical picture. The arbitrarily chosen CRP cut-off at 30 mg/L 
has later been supported by CRP analyses in healthy infants.14 We 
analysed antibiotic treatment duration in all infants in the pre- and 
post-implementation period, and focused on three groups: infants 
commenced on antibiotics but not diagnosed with sepsis, infants di-
agnosed with sepsis and all infants treated with antibiotics in the first 
week of life. Trends in overall antibiotic use in the three study hos-
pitals versus the other 18 Norwegian hospitals with a neonatal unit 
were compared using an already established benchmarking parameter 
from the NNN; mean days of antibiotic therapy among admitted in-
fants during the first two weeks of life.
Continuous variables are presented as median with interquartile 
range (IQR). Data were compared between groups using non-para-
metric tests for continuous variables and chi-square for categorical 
variables. P-values were 2-sided, and P < .05 was considered statisti-
cally significant. We present survival curves for duration of antibiotic 
therapy before and after the CPG implementation. Statistical anal-
yses were performed with IBM SPSS 25 for Mac (IBM Corporation) 
and Stata (V145, StataCorp).
3  | RESULTS
There were 11,477 and 10,790 live infants ≥ 34+0 weeks of gesta-
tion born before and after guideline implementation, respectively, in 





(n = 10,790) P value
Any antibiotic treatment, n (%) 284 (2.5) 195 (1.8) .001
Hospital, Antibiotic therapy/no. of newborns (%)
AHUS 122/5807 (2.1) 79/5303 (1.5) .016
OHT 111/3596 (3.1) 83/3596 (2.3) .042
UNN 51/2074 (2.5) 33/1891 (1.8) .12
Diagnosis, n (%)
No sepsis 120 (42) 105 (54) .015
Culture-negative sepsis 161 (57) 88 (45)
Culture-positive sepsis 3 (1.1) 2 (1.0)
Birthweight (grams), mean (SD) 3650 (682) 3642 (629) .90
Gestational age (weeks), median (IQR) 40 (39-41) 40 (38-41) .56
Caesarean delivery, n (%) 85 (30) 36 (18) .005
Respiratory support at start/during infection, n (%)
No 189 (67) 113 (58)  
CPAP/nHFT 78 (28) 72 (37)  
Ventilator 16 (6) 10 (5) .10
Abbreviations: AHUS, Akershus University Hospital; CPAP, continuous positive airway pressure; 
IQR, interquartile range; nHFT, nasal high-flow therapy; OHT, Ostfold Hospital Trust; SD, standard 
deviation; UNN, University Hospital of North Norway.
TA B L E  1   Background data on all 
neonates ≥ 34+0 weeks of gestation 
who received IV antibiotics in the three 
participating neonatal intensive care units
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Background data on patients admitted to the three NICUs and re-
ceiving antibiotic therapy are presented in Table 1. Three positive 
blood cultures were identified before (two viridans group strepto-
cocci and one Escherichia coli) and two positive blood cultures after 
(one Staphylococcus aureus and one viridans group streptococci) 
guideline implementation. Antibiotic treatment duration and pro-
portion of infants receiving antibiotics before and after guideline 
implementation are presented in Table 2.
The treatment duration for infants without sepsis did not change 
appreciably (Table 2). In infants without a sepsis diagnosis at discharge, 
antibiotic treatment had been continued beyond 48 hours in 49% be-
fore vs. 44% after the CPG (P = .65), but the treatment duration varied 
substantially between the three NICUs. After guideline implementa-
tion, the treatment duration for all infants, including those diagnosed 
with sepsis, was reduced (Table 2). Moreover, a lower proportion of 
infants were commenced on antibiotics (Table 1). Overall, there was a 
37% reduction in antibiotic days from 11.4 to 7.2/100 near-term and 
term infants. Figure 1 shows that antibiotic treatment duration was 
reduced more after guideline implementation in the two units using 
PCT versus the one not using PCT (P = .001).
Table 3 shows infection biomarkers in infants diagnosed with 
sepsis (P36.9) and those not diagnosed with sepsis. There were 
marked differences between the two groups. No patients were 
re-hospitalised with relapse within 14 days, or developed relevant 
sequelae or complications before or after guideline implementation.
There was a general trend in Norwegian NICUs to use less antibiot-
ics during 2016-2017, the period of this QI project (Figure 2). However, 
in 2017 after implementing the QI project there was a markedly larger 
reduction in antibiotic use in the three study hospitals than in the other 
18 Norwegian hospitals reporting data to the NNN.
4  | DISCUSSION
There is a wide variation in antibiotic use, both within countries and 
globally, but with little difference in infection-attributable morbidity 
and mortality.2,8,15 This may indicate an overuse of antibiotics in some 
NICUs and countries resulting in potentially adverse short- and long-
term consequences for the health of individual infants.4,16,17 In our 
QI project, the primary goal was to reduce the duration of antibiotic 
therapy in infants commenced on antibiotics, but who later did not have 
clear evidence of a bacterial infection, one of the top five items in the 
Choosing Wisely campaign for newborn medicine.5 We did not achieve 
our primary goal, but median treatment duration before and after in-
tervention in our study was 49 and 48 hours, respectively, half of the 
96 hours observed in the nationwide Norwegian study 2009-2011.8 
We also observed reductions in overall antibiotic use, including > 1/3 
reduction in antibiotic days per 100 live-born infants. Despite the com-
mon CPG and beneficial outcomes associated with the QI project, large 
differences persisted between the three participating NICUs.
An ASO policy to ensure continuation of antibiotics only in in-
fants considered to benefit from further therapy is more common 
in North America than Europe.10,11 In our QI project, the implemen-
tation of ASO was challenging, both in the units using manual drug 
prescription and in the unit using computerised prescription. This 
indicates that establishing the ASO as a routine policy requires stew-
ardship, in addition to more in-depth education of NICU staff.
In the two units using PCT to guide treatment discontinuation, 
the treatment duration in infants not diagnosed with sepsis was 
shorter than in the unit not using PCT. One of these units (OHT) had 
a reduction in both the proportion of neonates started on antibiotic 
treatment and the duration of treatment. The second unit (UNN) 
TA B L E  2   Antibiotic duration (hours) for different conditions and hospitals before and after implementation of a joint clinical practice 
guideline
 Pre-implementation N (%) Post-implementation N (%) P value
Antibiotic duration (hours) —All treated
Ahus 120 (84-155) 122 (2.1) 120 (72-144) 79 (1.5) .24
OHT 112 (60-136) 111 (3.1) 96 (47-120) 83 (2.3) .03
UNN 60 (24-98) 51 (2.5) 36 (24-72) 33 (1.8) .21
Total 108 (60-144) 284 (2.5) 96 (48-120) 195 (1.8) .013
Antibiotic duration (hours) —No sepsis
Ahus 72 (45-108) 39/122 (32) 72 (48-96) 37/79 (47) .67
OHT 48 (36-106) 47/111 (42) 47 (36-60) 40/83 (48) .19
UNN 43 (24-60) 34/51 (67) 36 (24-72) 28/33 (85) .98
Total 49 (31-84) 120/284 (42) 48 (36-72) 105/195 (54) .68
Antibiotic duration (hours)—Sepsis
Ahus 132 (108-156) 83/122 120 (120-168) 42/79 (53) .71
OHT 120 (108-148) 64/111 120 (108-122) 43/83 (52) .42
UNN 108 (96-120) 17/51 108 (84-108) 5/33 (15) .43
Total 120 (108-155) 164/284 120 (108-144) 90/195 (46) .73
Note: All data are median (interquartile range).
Abbreviations: AHUS, Akershus University Hospital; OHT, Ostfold Hospital Trust; UNN, University Hospital of North Norway.
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had neither a reduction in the proportion started on treatment, nor 
treatment duration, but this unit was nearly fully adhering to the main 
elements in the CPG before the QI project. This unit also had a signifi-
cantly lower proportion of infants diagnosed with P36.9 among all in-
fants commenced on antibiotics (15%) compared with the two other 
units who diagnosed 47%-48% of all infants commenced on antibi-
otics with P36.9. Our data indicate a considerable variation between 
the three hospitals regarding diagnostic regiments in suspected EOS. 
We believe that the policies and level of training are comparable be-
tween the centres, but that implementation of international recom-
mendations may depend on local champions and the size of the unit. 
The combination of a unit head with research focuses on neonatal in-
fections, and a lower number of patients and staff at UNN might have 
been facilitating factors in the earlier acquisition and implementation 
of international recommendations for treatment discontinuation.6,7
Our data may support that use of PCT can contribute to a re-
duction in antibiotic therapy duration as was observed in the large 
NeoPINS,9 but the low number of infants included in our study limits 
the conclusions that can be drawn.
Overall, fewer infants were commenced on antibiotic therapy and 
the duration of therapy for all infants commenced on therapy was 
shorter. The reduced proportion of neonates who was commenced on 
antibiotic treatment was an unintended effect of the project, and it was 
specifically not included as an aim in the QI project as it would have re-
quired a more thorough safety assessment. We can only speculate that 
an increased attention to unnecessary antibiotic use and its potential 
adverse effects in neonates, a fact recognised as a major health prob-
lem over the last 5-10 years,18 may have contributed to this surprising 
result. None of the participating NICUs used the neonatal early-onset 
sepsis calculator (NEOSC) and the main indications to start therapy were 
clinical symptoms in conjunction with abnormal biomarkers. The propor-
tion of infants exposed to antibiotic therapy after implementing the new 
CPG was only 1.8%. This is in line with data from a large Swiss neonatal 
unit where the rate of antibiotic use went down to 1.7% by focusing on 
clinical assessment rather than laboratory tests.19 Our overall antibiotic 
prescription rate is lower than that reported in the largest study evaluat-
ing the effects of the NEOSC where still 2.6% of all term and late preterm 
infants were treated with antibiotics during the first 24 hours of life.20
F I G U R E  1   (A) Duration of antibiotic therapy before and after 
implementing procalcitonin (PCT) as part of the clinical practice 
guideline—all newborns treated with antibiotics. (B): Duration of 
antibiotic therapy before and after implementing procalcitonin 
(PCT) as part of the clinical practice guideline—newborns without 
sepsis
TA B L E  3   Laboratory analyses for CRP and PCT in newborns 
with and without infectious diagnosis
 Sepsis** No sepsis P value*
CRP initial, n = 467 30 (3-55) 5 (1-16) <.001
CRP max 0-48 hours, n = 468 50 (32-70) 14 (4-28) <.001
PCT initial, n = 89 12 (5-29) 3 (1-15) .005
PCT max 24-36 hours, n = 64 10 (4-27) 2 (1-6) <.001
Note: All data are median (interquartile range).
CRP; C-reactive protein, mg/L; PCT; procalcitonin, µg/L.
*Wilcoxon rank-sum test. 
**In the sepsis group, there were five patients with culture-proven 
infection; Viridans group streptococci (n = 3), Staphylococcus aureus 
(n = 1) and Escherichia coli (n = 1). CRP ranged from 46 to 189 mg/L for 
this group. PCT was only taken in the infant with S aureus sepsis and 
was 1.49 µg/L. 
F I G U R E  2   Trends in overall antibiotic use among 
infants ≥ 34+0 weeks in the three study hospitals 2009-2017 
compared with trends in the other hospitals in the Norwegian 
neonatal network. Data presented as mean (95% confidence 
interval) days of antibiotic therapy among all infants admitted to 
the neonatal unit during the first two weeks of life
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Our study has limitations. We have not established a causal link be-
tween the new CPG and the decrease in antibiotic use. The observed 
reduction may mainly be due to the educational component of the QI 
project. Although we assessed a population of more than 20,000 in-
fants, the number of patients in our study was too low to conclude that 
the overall reduction in antibiotic use was safe. Given the low incidence 
of EOS, much larger studies are needed to be confident about safety 
measures. It was still reassuring that the overall reduction in antibiotic 
use was not associated with adverse events. Strengths of the study 
include the well-defined catchment area of the participating hospitals 
leading to population-based data and the development of a ‘modern’ 
CPG based on recent evidence, initiatives and guidelines.
5  | CONCLUSION
In this QI project, we did not observe a significant reduction in antibi-
otic therapy duration in infants commenced on antibiotic therapy for 
suspected EOS, which was later not confirmed. However, through 
a relatively simple intervention, overall antibiotic use was reduced 
without seemingly affecting safety. The educational part of the QI 
project may have had the most important impact, but we speculate 
that PCT analysis may aid in recognising not-infected infants where 
antibiotics may be stopped safely. An interesting finding was that 
some differences between the units persisted, possibly reflecting 
that it takes time to change established antimicrobial stewardship 
cultures. Further multicentre and national QI long-term initiatives 
are needed to reduce unwarranted variation in practice.
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